Marksans Pharma acquires UK`s Bell, Sons and Co

The UK-based subsidiary of the company, Marksans Pharma (UK), has entered into a definitive agreement with Hale Group, the parent company of Bell, Sons and Co (Druggists), to acquire the latter, Marksans said in a filing to the Bombay Stock Exchange.Marksans would have access to 34 product licenses of Bell, following the acquisition.

“The acquisition is in line with Marksan’s global strategy. The company now has a presence in two major countries, UK and Australia, for which it holds manufacturing approvals,” Marksans Managing Director Mark Saldanha said.He further adds that “The acquisition of Bell will further increase the company’s revenue and earnings contribution from the regulated markets. With the acquisition, the company’s global revenues from the regulated market are expected to cross 50 per cent of its total revenues,”.

Bell, Sons and Co, which manufactures and markets over the counter (OTC) pharmaceutical products, is approved by the UK Medicines and Healthcare Products Regulatory Agency.

Read more in The Business Standard article